AlphAIAlphAI — Financial news for AI agents
tradingview.com$HAE

Haemonetics Q2 Revenue Rises 9.3%; Raises Fiscal 2027 Revenue Guidance

Haemonetics reported Q2 fiscal 2027 revenue of $357.8M, up 9.3% YoY, with adjusted EPS of $1.35. Organic revenue grew 10.0%. The company raised fiscal 2027 revenue guidance to 8-11% from 5-8%. Growth was driven by Apheresis and MedSurg segments, with notable expansion in the CSL relationship.

Original reporting
tradingview.com
Published Nov 5, 2026, 11:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 11:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Haemonetics Q2 Revenue Rises 9.3%; Raises Fiscal 2027 Revenue Guidance — source image
Source · tradingview.com
Decision brief

The 30-second read

$HAEBullishHigh
01

Why it matters

The earnings beat and guidance lift provide a fresh catalyst that can move the stock in the near term.

02

Market read

First‑report earnings and guidance raise for a mid‑cap med‑tech firm; likely to influence short‑term price action.

03

What to watch

Potential supply‑chain constraints or slower adoption of new technologies could temper growth.

Relevance 8/10Novelty 8/10Timing: post‑market today

Background

Haemonetics' Q2 earnings release includes revenue, margin, and EPS figures, plus an upward revision of FY2027 guidance.

Company-level read

Ticker impact

$HAEBullishHigh confidence
Context

Haemonetics reported Q2 FY2027 revenue up 9.3% YoY and raised FY2027 revenue guidance to 8‑11% from 5‑8%, a fresh earnings disclosure.

Expected impact

likely upward pressure as the market prices in higher revenue expectations

Evidence & confidence

The company beat prior quarter results and lifted both reported and organic revenue guidance, a material catalyst for traders.

Market effects

Sector

Positive signal for the medical devices and blood‑management sector, may lift peers.

Regional

U.S. healthcare‑related stocks could see modest gains.

Global

Limited to investors focused on U.S. med‑tech equities.

Counterpoint

What could challenge this read

If the guidance raise is already priced in, the stock could face a short‑term pull‑back.

Key entities

  • company
    Haemonetics Corp

    Medical device maker that reported Q2 FY2027 results and raised guidance.

Read at source← All news

StoryHaemonetics posts Q2 FY2027 earnings beat and lifts full‑year revenue outlook

Also covered by

4 outlets

Related articles

$HAEMed

Mizuho raises Haemonetics stock price target on plasma strength

Mizuho raised its price target for Haemonetics (HAE) to $165 from $140, citing 18% organic plasma growth and improved guidance. The stock has gained 151% over the past year. HAE reported Q2 earnings of $1.35 per share, beating estimates, with revenue up 9.3% YoY. BTIG also raised its target to $142. Investors note margin guidance concerns and growth spending.

investing.com
$HAEHighAI 8/10

BTIG raises Haemonetics stock price target to $142 on earnings beat

BTIG raised its price target on Haemonetics (HAE) to $142 from $130, maintaining a Buy rating. HAE's Q2 2027 revenue was $357.8M, up 9.3% YoY, beating estimates. Adjusted EPS was $1.35, exceeding expectations. All segments performed well, with Apheresis revenue at $204.8M. Adjusted gross margin increased to 61.9%. HAE raised fiscal 2027 revenue guidance but reduced adjusted EBIT margin expansion outlook.

investing.com